An Hui Yi Pu Ke Yi Yao Ke Ji Fa Zhan You Xian Gong Si

Healthy Chinese subjects were used as test subjects. A self-crossover design was used to determine the time course of plasma concentration of Cinipride in healthy subjects after administration of Cinipride Tartrate Tablets licensed by Anhui Yipke Pharmaceutical Technology Development Co., Ltd., and to estimate the corresponding pharmacokinetic parameters. Cinipride Tartrate Tablets licensed by Almirall, S.A. [Trade name: Cidine®, specification: 1 mg (calculated as Cinipride)] were used as reference to evaluate the bioequivalence between the preparations and to observe the safety of Cinipride Tartrate Tablets in healthy Chinese subjects.

Healthy Chinese subjects were used as test subjects. A self-crossover design was used to determine the time course of plasma concentration of Cinipride in healthy subjects after administration of Cinipride Tartrate Tablets licensed by Anhui Yipke Pharmaceutical Technology Development Co., Ltd., and to estimate the corresponding pharmacokinetic parameters. Cinipride Tartrate Tablets licensed by Almirall, S.A. [Trade name: Cidine®, specification: 1 mg (calculated as Cinipride)] were used as reference to evaluate the bioequivalence between the preparations and to observe the safety of Cinipride Tartrate Tablets in healthy Chinese subjects.